Table 2.
Characteristics of Survey Participants
| Characteristic | No. in Sample | Mean (SD) or No. (%) | Median (IQR) |
|---|---|---|---|
| Demographics | |||
| Age, y | 101 | 36 (11) | 35 (17) |
| Sex, female | 101 | 52 (52%) | … |
| Clinical measures | |||
| BMI | 101 | 23 (3.2) | 23 (3.6) |
| ppFEV1 | 101 | 69 (22) | 69 (30) |
| Mild (> 70%)a | 101 | 50 (50%) | … |
| Moderate (40%-70%) | … | 39 (39%) | … |
| Severe (< 40%) | … | 12 (12%) | … |
| absFEV1, L | 99 | 2.5 (1.1) | 2.3 (1.4) |
| ppFVC | 94 | 85 (20) | 87 (27) |
| Absolute FVC, L | 94 | 3.7 (1.1) | 3.6 (1.5) |
| Diagnosis of GERD | 101 | 42 (42%) | … |
| Diagnosis of CFRD | 101 | 29 (29%) | … |
| Treatment characteristics | … | ||
| Treatment complexity score | 101 | 22 (7.4) | 23 (9) |
| Total treatment time, min/d | 103 | 92 (71) | 85 (65) |
| Physiotherapy time, min/d | 103 | 38 (33) | 30 (40) |
| Inhaled medicines time, min/d | 103 | 43 (38) | 30 (40) |
| No. chronic treatments | 101 | 13 (4.8) | 13 (5) |
| Prescribed CFTR modulator | 101 | 65 (65%) | … |
| Ivacaftor | 101 | 4 (4%) | … |
| Tezacaftor/ivacaftor | … | 29 (29%) | … |
| Elexacaftor/tezacaftor/ivacaftor | … | 33 (33%) | … |
| Received IV antibiotics in last year | 101 | 36 (36%) | |
| No. of IV antibiotic courses in last yearb | 36 | 2.6 (2.1) | 2 (3) |
| HRQoL and treatment burden measures | |||
| EQ-5D Index score | 103 | 0.77 (0.19) | 0.77 (0.2) |
| EQ-5D VAS score | 103 | 75 (16) | 80 (22) |
| CFQ-R treatment burden domain score | 103 | 54 (23) | 56 (33) |
| CFQoL treatment burden domain score | 103 | 64 (26) | 67 (40) |
absFEV1 = absolute FEV1; CFRD = cystic fibrosis-related diabetes; CFTR = cystic fibrosis transmembrane conductance regulator; CFQoL = cystic fibrosis-related quality of life; CFQ-R = Cystic Fibrosis Questionnaire-Revised; EQ-5D = EuroQol-5 Dimension; GERD = gastroesophageal reflux disease; HRQoL = health-related quality of life; IQR = interquartile range; ppFEV1 = FEV1 % predicted; VAS = visual analog scale.
a
Percentages do not sum to 100, due to rounding.
b
For those who received at least one IV antibiotic course.